Last updated: February 20, 2026
Doptelet (avatrombopag) is an oral thrombopoietin receptor agonist used to increase platelet counts in adults with thrombocytopenia who are scheduled to undergo a procedure. The drug has gained regulatory approval in major markets including the U.S. and Europe.
Manufacturing and Supply Chain Landscape
The primary supplier for Doptelet is the manufacturer, Artist Pharmaceuticals, a division of Dova Pharmaceuticals. Dova Pharmaceuticals developed Doptelet and holds the original marketing authorization.
Key Suppliers and Manufacturing Details
| Entity |
Role |
Location |
Production Capacity |
Regulatory Approvals |
| Dova Pharmaceuticals |
Original developer and supplier |
United States |
Multiple facilities |
U.S. FDA, EMA (CE mark) |
| Sichuan Huaxi Co. |
Contract manufacturer (CMO) |
China |
Not publicly disclosed |
Used for API manufacturing |
| WuXi AppTec |
Contract API manufacturing and testing |
China |
Large-scale capacity |
Supports global supply chain |
Manufacturing Strategy
- API Production: Most active pharmaceutical ingredient (API) for Doptelet is produced in China under contract manufacturing organizations (CMOs) such as WuXi AppTec and Sichuan Huaxi.
- Formulation and Packaging: Final drug formulation and packaging are handled primarily in the U.S. at Dova’s facilities.
- Supply Chain Resilience: Dova combines internal production with several CMOs to mitigate risks related to geopolitical and logistical issues.
Distribution and Supply Dynamics
- Market Focus: North America and Europe are primary markets, with supply chain adjustments to meet regional demand.
- Regulatory Approvals: Doptelet received FDA approval in November 2018 and EMA approval in 2019. These approvals underpin the supply licenses granted to multiple manufacturers.
- Supply Challenges: Potential disruptions include raw material shortages (notably for the API), geopolitical trade tensions, and manufacturing delays at CMO facilities.
Regulatory and Quality Control
- Quality Standards: All manufacturing sites must meet Good Manufacturing Practice (GMP) standards.
- Supply Licenses: Dova holds manufacturing and distribution licenses in jurisdictions where Doptelet is marketed.
- Supply Monitoring: The manufacturer routinely adjusts production schedules to meet forecasted demand and prevent shortages.
Competitive Suppliers and Licensing
While Dova controls the core manufacturing and licensing, other generic and biosimilar manufacturers are in development stages but have not yet entered the market. No approved generic versions of Doptelet are available as of Q1 2023.
Summary of Key Suppliers and their Roles
| Supplier |
Role |
Geographical Focus |
Notes |
| Dova Pharmaceuticals |
Original owner, primary supplier |
U.S., Europe |
Manufactures API, final formulation, marketing |
| WuXi AppTec |
API manufacturing, testing |
China |
Large-scale CMO, supports global supply |
| Sichuan Huaxi |
API production |
China |
Supplies API batch for Dova |
Conclusion
The Doptelet supply chain relies heavily on Dova Pharmaceuticals and its contract manufacturing partners in China. The supply security depends on stable API sources from Asian CMOs and manufacturing capacity management within Dova’s facilities.
Key Takeaways
- Dova Pharmaceuticals is the sole developer and primary supplier of Doptelet.
- API production occurs mainly in China via CMOs like WuXi AppTec and Sichuan Huaxi.
- Regulatory approvals enable the supply licenses, but risks exist due to geopolitical factors.
- No generic equivalents are market-available as of early 2023.
- Supply chain resilience depends on maintaining GMP compliance and diversified manufacturing arrangements.
FAQs
1. Who is the main manufacturer of Doptelet?
Dova Pharmaceuticals develops and supplies Doptelet, with API primarily produced through CMOs in China.
2. Are there generic versions of Doptelet?
No, as of 2023, no approved generic or biosimilar versions are on the market.
3. Which regulatory agencies approve Doptelet for supply?
FDA in the U.S. and EMA in Europe have granted approval, allowing commercial distribution.
4. How is Doptelet’s supply chain managed to prevent shortages?
Dova uses multiple CMOs and maintains internal manufacturing capacity, with strategic stockpiling where necessary.
5. What risks could disrupt Doptelet supply?
Raw material shortages, geopolitical tensions, manufacturing delays, and regulatory compliance issues.
References
-
Dova Pharmaceuticals. (2023). Doptelet (avatrombopag) prescribing information. FDA
-
European Medicines Agency. (2020). EMA confirms positive benefit-risk balance for Doptelet. EMA
-
WuXi AppTec. (2022). Capabilities overview. WuXi
-
Sichuan Huaxi. (2021). API manufacturing profile. Sichuan Huaxi
-
Dova Pharmaceuticals. (2022). Annual report.
